Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension
American Journal of Physiology-Lung Cellular and Molecular Physiology · 2025
DOI: 10.1152/ajplung.00303.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Lung Cellular and Molecular Physiology, 2025. Verfasst von Satomi Imakiire und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Interleukin-6, NF-kappa B, Hypertension, Pulmonary, Thiazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Mochida Pharmaceutical Company, Astellas Pharma (Astellas).
Abstract (Originalsprache)
This study demonstrated that chronic treatment with activated factor X (FXa) inhibitor ameliorated NF-κB-IL-6-mediated perivascular inflammation in a rat model with pulmonary arterial hypertension, which is associated with elevated FXa activity. FXa may act on pulmonary arterial smooth muscle cells, inducing cell proliferation and inflammatory response via upregulated PAR 1 , thereby contributing to pulmonary vascular remodeling. Understanding the patient-specific pathophysiology is a prerequisite for applying FXa-targeted therapy to the treatment of pulmonary arterial hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Division of Cardiovascular Medicine, Faculty of Medical Sciences, Research Institute of Angiocardiology, Kyushu University, Fukuoka, Japan.
- Department of Cardiovascular Medicine, Okayama University, Okayama, Japan.
- Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
- School of Medicine and Graduate School, International University of Health and Welfare, Okawa, Japan.
ORCID-Profile: Keimei Yoshida, Kohei Masaki, Kazuya Hosokawa, Toru Hashimoto, Keisuke Shinohara, Kazufumi Nakamura, Katsuya Hirano
Förderung
- Mochida Pharmaceutical Company
- Astellas Pharma (Astellas)
Zitieren
APA
Imakiire, S., Kimuro, K., Yoshida, K., Masaki, K., Izumi, R., Imabayashi, M., Watanabe, T., Ishikawa, T., Hosokawa, K., Matsushima, S., Hashimoto, T., Shinohara, K., Katsuki, S., Matoba, T., Nakamura, K., Hirano, K., Tsutsui, H., & Abe, K. (2025). Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.00303.2024
Vancouver
Imakiire S, Kimuro K, Yoshida K, Masaki K, Izumi R, Imabayashi M, et al. Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2025. doi:10.1152/ajplung.00303.2024
BibTeX
@article{Imakiire2025,
author = {Imakiire, Satomi and Kimuro, Keiji and Yoshida, Keimei and Masaki, Kohei and Izumi, Ryo and Imabayashi, Misaki and Watanabe, Takanori and Ishikawa, Tomohito and Hosokawa, Kazuya and Matsushima, Shouji and Hashimoto, Toru and Shinohara, Keisuke and Katsuki, Shunsuke and Matoba, Tetsuya and Nakamura, Kazufumi and Hirano, Katsuya and Tsutsui, Hiroyuki and Abe, Kohtaro},
title = {Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension},
journal = {American Journal of Physiology-Lung Cellular and Molecular Physiology},
year = {2025},
doi = {10.1152/ajplung.00303.2024}
}
EUVIMED